1. Home
  2. SOC vs TOVX Comparison

SOC vs TOVX Comparison

Compare SOC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SOC
  • TOVX
  • Stock Information
  • Founded
  • SOC 2020
  • TOVX 2001
  • Country
  • SOC United States
  • TOVX United States
  • Employees
  • SOC N/A
  • TOVX 22
  • Industry
  • SOC
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SOC
  • TOVX Health Care
  • Exchange
  • SOC Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • SOC 2.1B
  • TOVX 3.2M
  • IPO Year
  • SOC N/A
  • TOVX 2006
  • Fundamental
  • Price
  • SOC $22.28
  • TOVX $1.14
  • Analyst Decision
  • SOC Buy
  • TOVX Strong Buy
  • Analyst Count
  • SOC 3
  • TOVX 1
  • Target Price
  • SOC $25.00
  • TOVX $6.00
  • AVG Volume (30 Days)
  • SOC 1.6M
  • TOVX 97.3K
  • Earning Date
  • SOC 11-14-2024
  • TOVX 11-12-2024
  • Dividend Yield
  • SOC N/A
  • TOVX N/A
  • EPS Growth
  • SOC N/A
  • TOVX N/A
  • EPS
  • SOC N/A
  • TOVX N/A
  • Revenue
  • SOC N/A
  • TOVX N/A
  • Revenue This Year
  • SOC N/A
  • TOVX N/A
  • Revenue Next Year
  • SOC $606.07
  • TOVX N/A
  • P/E Ratio
  • SOC N/A
  • TOVX N/A
  • Revenue Growth
  • SOC N/A
  • TOVX N/A
  • 52 Week Low
  • SOC $10.11
  • TOVX $1.14
  • 52 Week High
  • SOC $28.67
  • TOVX $17.00
  • Technical
  • Relative Strength Index (RSI)
  • SOC 53.11
  • TOVX 36.15
  • Support Level
  • SOC $19.51
  • TOVX $1.23
  • Resistance Level
  • SOC $24.73
  • TOVX $1.21
  • Average True Range (ATR)
  • SOC 1.60
  • TOVX 0.07
  • MACD
  • SOC 0.12
  • TOVX 0.01
  • Stochastic Oscillator
  • SOC 58.60
  • TOVX 0.00

About SOC Sable Offshore Corp. Common Stock

Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: